Q4
1.6.2022 15:02:07 CEST | Business Wire | Press release
Q4 Inc. (TSX: QFOR) (“Q4”), a leading capital markets communications platform provider, is excited to announce the launch of Q4 Capital Connect ™, a revolutionary, scalable platform built to streamline workflows and provide data-driven strategic insights across the capital markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005573/en/
Q4 Capital Connect™ enables public companies across all industries and market caps to seamlessly launch and measure the impact of a complete investor relations strategy. With one place to launch how they communicate their value to the markets, analyze the impact of every outreach, target and engage with the right investors, IR teams can build a repeatable, proactive strategy to connect with the capital markets. The platform approach allows all data generated by investors across an IR program to be aggregated alongside shareholder analytics for insights to shape a communication strategy that investors value while identifying and prioritizing the shareholders that matter.
The Q4 Capital Connect platform will house a portfolio of future applications, purpose-built to empower capital markets professionals. The first of these applications include Q4 Engagement Analytics and Q4 Web Management .
The Engagement Analytics application on Q4 Capital Connect™ aggregates the actions of investors and shareholders visiting an investor relations website and IR-related events, turning behavioral data into powerful leading indicators of stock movement, ownership data and surveillance to drive a new and proactive approach to investor targeting. Through these analytics, IROs can identify which new, existing or targeted institutions are assessing content, analyze interactions at the early stages of an investor’s research, prioritize their management team’s time to proactively engage with the right investor, and accelerate management’s awareness of activist interest in the company.
Engagement Analytics is the first product in the market that uniquely combines investor behavior with the buying and selling of publicly traded securities. This provides the ability to understand investors’ actions and intent on a daily basis and takes proactive targeting to a new level.
The fully integrated Web Management application on Q4 Capital Connect™ provides a frictionless and simplified approach to managing an IR website, offering one destination to request, track and approve critical updates to the market. Q4’s secure platform connects users with the Q4 Content Services team to easily request, preview, and publish changes to their website, while tracking change history in the same place. To date there are over 1,300 Q4 clients already using the web management application, who have experienced up to a 57% reduction in interactions when requesting content updates, a 35% improvement in turnaround times, and a vastly improved overall user experience.
“The launch of Q4 Capital Connect™ is just the beginning of a transformational approach to drive strategic, efficient and more effective interactions across the capital markets,” said Darrell Heaps, Q4’s CEO. “Built on proprietary data and analytics, along with an ever increasing portfolio of digital communication solutions, Q4 Capital Connect is a scalable platform that will continue to expand to an increasing number of applications for investor relations, as well as key workflows for investment banks and investors. We are very excited to introduce Q4 Capital Connect™ and demonstrate the strategic value and efficiencies we can provide to all capital markets participants when they come onto the Q4 platform.”
To learn more about Q4 Capital Connect™ please click here .
About Q4 Inc.
Q4 Inc. (TSX: QFOR) is a leading capital markets communications platform that is transforming the way publicly traded companies, investors and investment banks make decisions to efficiently discover, communicate and engage with each other. The Q4 end-to-end technology platform facilitates interactions across the capital markets through its IR website products, virtual events solutions, capital markets CRM, shareholder and market analytics tools. The firm is a trusted partner to more than 2,700 public companies globally including many of the most respected brands in the world. Q4 is based in Toronto, with offices in New York and London. Learn more at q4inc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005573/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom